CONSHOHOCKEN, PA — Cencora, Inc. (NYSE: COR) posted higher revenue and profits in its fiscal third quarter, driven by growth in both U.S. and international healthcare operations, and raised its full-year earnings guidance.
Revenue for the quarter ended June 30 rose 8.7% year-over-year to $80.7 billion, fueled by an 8.5% increase in U.S. Healthcare Solutions sales and a 10.5% gain in International Healthcare Solutions. GAAP diluted earnings per share climbed 45.5% to $3.52, while adjusted diluted EPS grew 19.8% to $4.00.
Gross profit jumped 20.6% to $2.9 billion, boosted by higher margins in the U.S. segment following the January acquisition of Retina Consultants of America and a favorable LIFO credit. Operating income rose 29% to $900 million, despite a 17.3% rise in operating expenses tied to the RCA acquisition and business expansion.
U.S. Healthcare Solutions generated $72.9 billion in revenue, with operating income up 29.1% on stronger demand for GLP-1 diabetes and weight-loss therapies and specialty medicines. International Healthcare Solutions revenue grew to $7.8 billion, though operating income fell 12.9% due to weaker results in global specialty logistics and consulting services.
Cencora lifted its fiscal 2025 adjusted EPS guidance to $15.85–$16.00 from $15.70–$15.95, citing stronger U.S. segment performance. The company now expects overall revenue growth of about 9% and adjusted operating income growth of 15–16%. U.S. operating income is projected to rise 20–21%, while international segment income is forecast to fall around 6%.
President and CEO Robert P. Mauch credited the results to the company’s pharmaceutical-centric strategy, investments in growth initiatives, and productivity gains.
The board declared a quarterly dividend of $0.55 per share, payable September 3 to shareholders of record as of August 15.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.